glp-1 obesity drug market forecast 2030 Size to Hit USD 66.57 Billion by 2035 The outlook for obesity from

Brain-Derived Neurotrophic Factor (BDNF), a neuropeptide integral to synaptic development, plays a key role in the central nervous system (Wang et al., 2022)

We prioritize patient safety and personalized care

Most GLP-1 and dual GIP/GLP-1 agonists are injected

Because of the slowed gastric emptying, many patients have gastrointestinal side effects that can often limit a patients ability to take these drugsespecially at the high doses recommended for weight loss

Holst also comments It was truly fantastic

Head-to-head efficacy comparison Retatrutide versus semaglutide is not even close in terms of raw weight loss numbers